Sosei Heptares acquires Idorsia's pharma business in Japan and beyond

20 July 2023

The Sosei Group Corporation (TYO: 4565) has acquired Swiss biotech Idorsia’s (SIX: IDIA) pharma business in Japan and Asia Pacific, excluding China.

In those territories, the group - which goes by the brand name Sosei Heptares - picks up rights to a pipeline of medicines from Idorsia’s portfolio, with lead product Pivlaz (clazosentan) already commercially available and with fast-growing sales in Japan following a successful launch last year.

"A step change in delivering on our ambitious growth strategy"Another drug seen as having significant growth potential is daridorexant. A Japanese filing is expected next year for insomnia for a product that is marketed in the USA and Europe as Quviviq.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK